Browse the evidence

Androgen excess drives metabolic dysfunction in PCOS by promoting visceral adiposity, inducing insulin resistance through adipocyte hypertrophy and reduced adiponectin, and suppressing brown adipose tissue thermogenesis.

For women with PCOS, metabolic issues like insulin resistance and visceral fat accumulation are strongly linked to high androgen levels, not just diet. Treating the hormonal imbalance (e.g., via anti-androgens or insulin-sensitizers) may be necessary to address metabolic health, as lifestyle changes alone may be insufficient if androgen excess persists.

Insulin resistance in PCOS is characterized by selective ovarian insulin resistance (hyper-sensitivity) alongside peripheral resistance, which exacerbates androgen production.

Standard insulin-sensitizing treatments (like metformin) can help lower androgens by reducing insulin levels, which in turn reduces the ovarian stimulation of androgen production.

A lower omega-6 to omega-3 ratio (specifically 2.5:1) reduces rectal cell proliferation in patients with colorectal cancer, whereas a ratio of 4:1 with the same amount of omega-3s had no effect.

If managing colorectal cancer risk, aim for a very low omega-6 to omega-3 ratio (around 2.5:1). This requires significantly reducing seed oils (corn, soy, sunflower) while increasing omega-3 sources. Simply taking fish oil pills without changing your background fat intake may not provide the same anti-proliferative benefits.

Estrogen rapidly activates AMP-activated protein kinase (AMPK) in skeletal muscle via non-genomic mechanisms, promoting fat oxidation and down-regulating lipogenesis.

Estrogen helps your muscles burn fat quickly by turning on an energy sensor called AMPK. This happens fast, suggesting estrogen has immediate metabolic benefits beyond long-term structural changes.

Estrogen increases perilipin protein levels in adipocytes, which suppresses basal lipolysis but significantly enhances catecholamine-stimulated lipolysis.

Estrogen helps your fat cells release stored fat more efficiently when stimulated by stress or exercise (catecholamines) by increasing a protective protein called perilipin. This makes your fat cells more responsive to signals that tell them to burn fat.

Rotating night shift work (defined as ≥3 night shifts per month) is associated with a statistically significant but small absolute increase in coronary heart disease (CHD) risk in women, with risk increasing in a duration-dependent manner (≥5 years exposure).

For women in rotating night shift roles (≥3 nights/month), long-term exposure (≥5 years) is linked to a modestly higher risk of heart disease. The risk appears to be most relevant during active exposure and decreases after stopping shift work. Regular cardiovascular monitoring is advisable for those with this work history, particularly if they have other risk factors like obesity.

The increased CHD risk associated with rotating night shift work wanes over time after cessation of the shift work.

If you have worked rotating night shifts, your heart disease risk decreases the longer you have been off those shifts. Stopping rotating night work is a beneficial health decision.

Steatosis biomarkers (FLI, NAFLD-LFS, HSI, VAI, TyG) are strongly correlated with insulin resistance (HOMA-IR) independently of the actual amount of liver fat.

These tests are best used to assess your overall metabolic risk (insulin resistance) rather than just liver fat. A high score suggests you are at higher risk for diabetes and cardiovascular issues, regardless of how much fat is actually in your liver.

Lean NAFLD, defined as fatty liver in non-obese individuals, is a significant subset of NAFLD (7-20%) and is associated with insulin resistance and metabolic dysfunction despite normal BMI.

You do not need to be overweight to develop fatty liver. Lean NAFLD affects 7-20% of NAFLD cases and is linked to insulin resistance and metabolic issues. If you have fatty liver, focus on metabolic health markers like blood sugar and insulin sensitivity, not just your weight.

Roux-en-Y gastric bypass (RYGB) achieves superior and durable weight loss compared to purely restrictive procedures (like VBG or AGB) primarily through hormonal mechanisms—specifically the suppression of ghrelin and enhancement of incretins (GLP-1, PYY)—rather than gastric restriction or malabsorption alone.

If you are considering Roux-en-Y gastric bypass, understand that its success relies less on the small stomach pouch size and more on hormonal changes. The surgery suppresses the hunger hormone ghrelin and increases satiety hormones like GLP-1 and PYY. This hormonal shift reduces appetite and improves glucose tolerance, often before significant weight loss occurs. This distinguishes it from purely restrictive surgeries which often fail long-term because they do not alter these hormonal signals.

Acute exercise induces mitophagy in skeletal muscle via an AMPK-dependent phosphorylation of Ulk1 at Serine 555, which is required for targeting damaged mitochondria to lysosomes.

Regular exercise triggers a specific cellular cleanup process (mitophagy) that removes damaged mitochondria. This process is driven by the AMPK-Ulk1 signaling pathway. To ensure this cleanup happens, consistent aerobic exercise is required to activate AMPK, which then phosphorylates Ulk1 to target damaged organelles for degradation.

AMPK is required for exercise-induced mitophagy, as blocking AMPK activity abolishes the increase in mitophagic markers (pure red puncta) following exercise.

If your AMPK pathway is impaired (e.g., due to metabolic disease or specific genetic factors), your body may fail to perform the necessary cleanup of damaged mitochondria after exercise, potentially blunting long-term health benefits.

Ulk1 is required for the targeting of mitochondria to lysosomes during exercise-induced mitophagy, but is not required for lysosomal biogenesis itself.

Ulk1 acts as a specific tagger that directs damaged mitochondria to lysosomes for destruction. Without Ulk1, the cell may still produce more lysosomes, but it fails to effectively target and degrade the damaged mitochondria.

Central administration of recombinant OB protein (leptin) reduces food intake and body weight in lean and ob/ob mice, demonstrating that the protein acts on central neural networks to regulate energy balance.

This paper establishes that leptin (OB protein) is a key hormone that signals fat stores to the brain to regulate eating and energy use. While this review focuses on animal models, it lays the groundwork for understanding why obesity is a biological condition. Future treatments may target this pathway to help regulate body weight.

Obese humans have elevated serum OB protein concentrations that correlate with body fat percentage, suggesting that human obesity is not caused by a deficiency in OB protein but potentially by reduced brain sensitivity to it.

This paper indicates that obese individuals typically have higher levels of OB protein (leptin) than lean individuals. This suggests that obesity is not caused by a lack of this hormone, but potentially by the body's reduced ability to respond to it or transport it to the brain.

Menopause, particularly when occurring early or via surgical removal of ovaries, accelerates biological aging as measured by epigenetic age acceleration in blood.

This research indicates that the hormonal changes of menopause, especially if early or surgical, may speed up biological aging in blood. While you cannot reverse menopause, being aware of this accelerated biological aging might motivate discussions with healthcare providers about hormone therapy or other strategies to support long-term health, as hormonal changes appear to leave a mark on your body's molecular aging clock.

Menopausal Hormone Therapy (MHT) is associated with lower epigenetic age acceleration in buccal epithelium, suggesting a potential protective effect against epigenetic aging in this tissue.

This study found that women using Menopausal Hormone Therapy (MHT) had lower epigenetic age in their cheek cells (buccal epithelium) compared to non-users. This suggests MHT might help slow biological aging in this specific tissue. However, this effect was not seen in blood, so the overall benefit is complex. Discuss the potential benefits and risks of MHT with your healthcare provider.

Surgical menopause (bilateral oophorectomy) before age 50 is associated with increased epigenetic age acceleration in both blood and saliva.

If you undergo surgical removal of your ovaries before age 50, this study suggests it may accelerate biological aging in your blood and saliva. This highlights the importance of discussing long-term health strategies, such as hormone therapy, with your doctor to manage these potential effects.

Elevated expression of the TXNIP gene in human skeletal muscle and adipose tissue directly inhibits both basal and insulin-stimulated glucose uptake, acting as a key mediator of insulin resistance.

High levels of TXNIP in your muscles and fat cells block your body's ability to use glucose efficiently, contributing to insulin resistance. While you cannot directly 'dose' TXNIP, understanding that insulin normally suppresses this gene suggests that maintaining insulin sensitivity through lifestyle factors (like exercise and diet) may help keep TXNIP levels low, thereby supporting healthy glucose uptake.

Amino acid availability, specifically leucine and arginine, regulates cellular protein synthesis and autophagy via the mTORC1 signaling pathway, where depletion inactivates mTORC1 to trigger autophagy and reduce protein biosynthesis.

To maximize muscle protein synthesis, ensure your diet provides sufficient leucine and arginine to activate the mTORC1 pathway. If these amino acids are depleted, your body shifts to breaking down its own proteins via autophagy. This means the quality and specific amino acid profile of your protein intake matter as much as the total amount.

Elevated plasma levels of Trimethylamine N-oxide (TMAO) are associated with an increased risk of major adverse cardiovascular events, atherosclerosis, and mortality in patients with chronic kidney disease.

If you have Chronic Kidney Disease, high TMAO levels are a strong predictor of heart problems and death. While you should still eat a balanced diet, be aware that high intake of choline (eggs, red meat) and carnitine (red meat) can lead to TMAO production by gut bacteria, potentially increasing cardiovascular risk. Discuss dietary precursors with your nephrologist.

Therapeutic strategies to reduce TMAO levels, including broad-spectrum antibiotics, dietary restriction of precursors, and specific inhibitors like 3,3-dimethyl-1-butanol (DMB), can attenuate atherosclerosis and cardiovascular risk.

Inhibiting TMA production (e.g., via DMB found in some vinegars/oils) or reducing choline/carnitine intake may lower TMAO and protect against atherosclerosis in animal models. Human applications are not yet standard.

Obesity acts as a chronic overload stimulus on antigravity muscles (e.g., quadriceps, calf), resulting in higher absolute maximum muscle strength compared to non-obese individuals, regardless of age.

If you are obese, your muscles (especially legs and back) are likely stronger in absolute terms than those of a non-obese person of similar height/age. This is because carrying extra weight acts like constant resistance training. However, this strength is 'diluted' by your body weight, making functional tasks feel harder. Building more muscle may not be as effective for mobility as losing weight, because the mechanical load of fat continues to offset strength gains.

In Type 2 Diabetes (T2D), beta cell functional impairment is an early predictor of disease progression, often preceding significant loss of beta cell mass.

In T2D, restoring beta cell function (e.g., through weight loss or bariatric surgery) can reverse diabetes rapidly, often before any significant change in beta cell mass occurs. Focus on functional recovery.